(PharmaNewsWire.Com, January 13, 2017 ) Ovarian cancer (OC; International Classification of Diseases, Revision 10 [ICD-10] code: C56) and cancer of the fallopian tubes and other uterine adnexa (ICD-10: C57) are leading causes of cancer mortality in women. Cancer of the ovary, fallopian tubes, and other uterine adnexa are collectively referred to as OC throughout this report. In the US, the American Cancer Society reports that OC accounts for more deaths than any other cancer of the female reproductive system.
Epidemiologists forecast the diagnosed incident cases of OC in the 7MM, to increase from 68,804 cases in 2015 to 77,457 cases in 2025, at an Annual Growth Rate (AGR) of 1.26%. The US will have the highest number of diagnosed incident cases of OC in the 7MM throughout the forecast period. The five year diagnosed prevalent cases of OC are also expected to increase from 191,345 cases in 2015 to 218,905 cases in 2025, at an AGR of 1.44%. Additionally, in 2015, there were 191,345 five-year diagnosed prevalent cases of OC in the 7MM, which is expected to increase to 218,905 cases by 2025, at an AGR of 1.44%. Among the 7MM, the US had the highest number of five-year diagnosed prevalent cases of OC in 2015 and 2025, at 73,597 cases and 89,778 cases, respectively.
Publisher's epidemiological forecast for the diagnosed incident and five-year diagnosed prevalent cases of OC in the 7MM is supported by age- and sex-specific incidence data drawn from national cancer registries. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific population-based studies that are representative of the national population in the respective markets. The use of a consistent methodology across the 7MM to forecast the diagnosed incident cases and the five-year diagnosed prevalent cases of OC allows for a meaningful comparison of the forecast diagnosed incident cases and the forecast five-year diagnosed prevalent cases of OC in these markets.
- The Ovarian Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for OC in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) . It includes a 10-year epidemiological forecast of the diagnosed incident cases of OC segmented by sex, age (beginning at 18 years and ending at =85 years) . Additionally, it includes a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of OC and in these markets. - The OC epidemiology report is written and developed by Masters- and PhD-level epidemiologists. - The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The OC EpiCast report will allow you to - - Develop business strategies by understanding the trends shaping and driving the global OC market. - Quantify patient populations in the global OC market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for OC therapeutics in each of the markets covered.
Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 5 2 Epidemiology 6 2.1 Disease Background 6 2.2 Risk Factors and Comorbidities 6 2.3 Global Trends 7 2.3.1 7MM Incidence Trends 7 2.3.2 7MM Trends in Relative Survival 8 2.4 Forecast Methodology 8 2.4.1 Sources Used Tables 8 2.4.2 Forecast Assumptions and Methods 10 2.4.3 Sources Not Used 13 2.5 Epidemiological Forecast for Ovarian Cancer (2015-2025) 13 2.5.1 Diagnosed Incident Cases of Ovarian Cancer 13 2.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer 15 2.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer 16 2.5.4 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer 17 2.6 Discussion 19 2.6.1 Epidemiological Forecast Insight 19 2.6.2 Limitations of the Analysis 19 2.6.3 Strengths of the Analysis 20 3 Appendix 21 3.1 Bibliography 21 3.2 About the Authors 23 3.2.1 Epidemiologists 23 3.2.2 Reviewers 23 3.2.3 Global Director of Therapy Analysis and Epidemiology 25
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
